A Phase III Randomized, Observer-Blind, Placebo-Controlled Study to Demonstrate the Efficicay of Respiratory Syncytical Virus (RSV) Recombinant F Nanoparticale Vaccine in Prevention of Acute, Symptomatic RSV-Associated Respiratory Disease, and Acute